Highlights From Milan 2025

Bispecific Antibodies in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma CME/CNE/CPE

Thursday, 19 June 2025 | 13:00 - 13:30 TZ
event presence logo
Supported by an independent educational grant from Genmab US, Inc. and Abbvie.

overview

Did you hear the latest news on bispecific antibodies in FL and DLBCL from the 2025 Hematology Congress in Milan? Join this live activity to hear our expert faculty review the most recent clinical trial data in the rapidly evolving field of bispecific antibodies in FL and DLBCL. Through engaging discussions and precision assessment of the data you will gain insights into treatment selection, adverse event management, and the impacts for your practice. Learn best practices for integrating these innovative agents into patient care while emphasizing the importance of patient-centered strategies. Enhance your clinical practice and knowledge—reserve your spot today!

Enhance Your Experience With MedChallenge!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

faculty

MODERATOR

Chan Cheah, MBBS, DMSc

Professor

Consultant Hematologist

Sir Charles Gairdner Hospital

Perth, Australia

PANELIST

Matthew Lunning, DO, FACP

Associate Professor

Medical Director, Cellular Therapy

Associate Vice-Chair Research, Department of Medicine

Assistant Vice Chancellor for Clinical Research

Fred & Pamela Buffett Cancer Center

University of Nebraska Medical Center

Omaha, Nebraska, United States

AGENDA

13:00 TZ

Welcome and Introduction

13:05 TZ

Bispecific Antibodies in DLBCL

13:15 TZ

Bispecific Antibodies in FL

13:25 TZ

Audience Q&A

backstage pass
Enhance Your Virtual Experience With Backstage Pass! Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.
*Video encouraged*

TARGET AUDIENCE

This educational activity is intended for a global audience of hematologists/oncologists, oncology nurse/nurse practitioners, and oncology pharmacists.

GOAL STATEMENT

The goal of this activity is for learners to be better able to summarize the clinical data presented on bispecific antibodies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) at the 2025 Hematology Congress in Milan.

LEARNING OBJECTIVES

[bold]Upon completion of this activity, participants will:[/bold] [para]Have increased knowledge regarding the[/para] [list][item]Clinical trial data on bispecific antibodies in FL [item]Clinical trial data on bispecific antibodies in DLBCL [/list] [para]Demonstrate greater confidence in their ability to [/para] [list][item]Assess the potential impact of recent data on bispecific antibodies in lymphoma on future clinical practice [/list]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
accreditation logo
medscape logo
[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 0.5 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text] [break] [title]For Nurses[/title] [text]Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs.[/text] [break] [title]For Pharmacists[/title] [text]Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-25-175-L01-P).[/text]
© 2025 MedscapeLIVE! All Rights Reserved | Medscape Education Terms of Service | Privacy Policy